The clinical potential of etrolizumab in ulcerative colitis: Hypes and hopes

Research output: Contribution to journalReview article

Abstract

Antiadhesion molecules are effective and safe in patients with ulcerative colitis (UC). Etrolizumab, a monoclonal antibody targeting both α4β7 and αEβ7, represents a promising therapy for patients with UC, since this novel mechanism of action may be effective in blocking leukocyte recruitment both at the vascular and at the mucosal level. Preliminary studies show that etrolizumab is effective in inducing clinical response and remission, and mucosal healing. Moreover, new predictors of response have recently been identified, opening the way to a tailored therapeutic approach. This review of the literature aims to present and discuss the most recent evidence on etrolizumab in UC, focusing on the clinical implications of the use of etrolizumab in UC.

Original languageEnglish
Pages (from-to)503-512
Number of pages10
JournalTherapeutic Advances in Gastroenterology
Volume9
Issue number4
DOIs
Publication statusPublished - Jul 1 2016

    Fingerprint

Keywords

  • anti-integrins
  • etrolizumab
  • inflammatory bowel disease
  • ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this